Interfering with chemokine networks - the hope for new therapeutics

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 407-417

  Schwarz, Matthias K ^a   Wells, Timothy Nc ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; IMMUNOMODULATING AGENT;

ANGIOGENESIS; CELL MIGRATION; CHEMOTAXIS; CYTOLOGY; EMBRYO DEVELOPMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; REVIEW; THERAPY; TRANSGENIC MOUSE; VIRUS INFECTION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS MUSCULUS;

EID: 0033179333     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80061-1     Document Type: Article

References (69)

1. Wells TNC, Power CA, Proudfoot AEI: Definition, function and pathophysiological significance of chemokine receptors. Trends Pharmacol Sci 1998, 19:376-380.
2. Schall TJ, Bacon K, Toy KJ, Goeddel DV: Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990, 347:669-671.
3. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, Menon S, Foster J, Xu Y, Nooyen P, McClanahan T et al.: A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997, 387:713-717.
4. Berger EA: HIV entry and tropism: The chemokine receptor connection. AIDS 1997, 11:S3-S16.
5. Proudfoot AEI, Wells TNC, Clapham PR: Chemokine receptors - future therapeutic targets for HIV? Biochem Pharmacol 1999, 57:451-463.
6. Wells TNC, Peitsch M: The chemokine information source: Identification and characterization of novel chemokines using the worldwideweb and expressed sequence tag databases. J Leukocyte Biol 1997, 61:545-550.
7. Wells TNC, Schwartz TW: Plagiarism of the host immune system: Lessons about chemokine immunology from viruses. Curr Opin Biotechnol 1997, 8:741-748.
8. Bonecchi R, Polentarutti N, Luini W, Borsatti A, Bernasconi S, Locati M, Power CA, Proudfoot AEI, Wells TNC, Mackay C et al.: Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN- gamma in human neutrophils. J Immunol 1999, 162:474-479.
9. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI: Structure and functional expression of a human interleukin-8 receptor. Science 1991, 253:278-280.
10. Murphy PM, Tiffany HL: Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991, 253:1280-1283.
11. Bacon KB, Premack BA, Gardner P, Schall TJ: Activation of dual T cell signaling pathways by the chemokine RANTES. Science 1995, 269:1727-1730.
12. Bacon KB, Szabo MC, Yssel H, Boten JB, Schall TJ: RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells. J Exp Med 1996, 184:873-882.
13. Alcami A, Symons JA, Collins PD, Williams TJ, Smith GL: Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol 1998, 160:624-633. With [14], these papers identify viral proteins that bind chemokines with sub-nanomolar potency. The proteins themselves may be therapeutically useful, and the structure of the chemokine-binding protein complex may give hints for drug design.
14. Lalani AS, Ness TL, Singh R, Harrison JK, Seet BT, Kelvin DJ, MacFadden G, Moyer RW: Functional comparisons among members of the poxvirus t1/35kDa family of soluble cc-chemokine inhibitor glycoproteins. Virology 1998, 250:173-184.
15. Rot A: Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur J Immunol 1993, 23:303-306.
16. Hoogewerf AJ, Kuschert GS, Proudfoot AEI, Borlat F, Clark LI, Power CA, Wells TNC: Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 1997, 36:13570-13578.
17. Spillmann D, Witt D, Lindahl U: Defining the interleukin-8-binding domain of heparan sulfate. J Biol Chem 1998, 273:15487-15493.
18. Kuschert GS, Hoogewerf AJ, Proudfoot AE, Chung CW, Cooke RM, Hubbard RE, Wells TN, Sanderson PN: Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry 1998, 37:11193-11201.
19. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwanz TW, BuseR R, Wells TNC, Proudfoot AEI: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5-antagonist. Science 1997, 276:276-279.
20. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, Signoret N, Marsh M, Stangassinger M, Borlat F et al.: Aminooxypentane-rantes induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J Exp Med 1998, 187:1215-1224.
21. Opperman M, Mack M, Proudfoot AEI, Olbrich H: Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. J Biol Chem 1999, 274:8875-8885. With [20], these papers show differences in the signalling pathways that may be crucial for control of receptor cycling.
22. Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, Daugherty BL, Springer MS, Durham SR et al.: Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997, 27:3507-3516.
23. Gonzalo JA, Lloyd CM, Kremer J, Finger E, Martinez AC, Siegelman MH, Cybulsky M, Gutierrez-Ramos JC: Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T-cells, chemokines and adhesion receptors. J Clin Invest 1996, 98:2332-2345.
24. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinerti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM et al.: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999, 103:807-815. This paper discusses critical observations of the role of chemokines and their receptors in multiple sclerosis. The data fit well with what would be expected of a T helper lymphocyte type 1-mediated disease.
25. Cacalano G, Lee J, Kikly K, Ryan AM, Pitts-Meek S, Hultgren B, Wood WI, Moore MW: Neutrophil and B-cell expansion in mice that lack the murine IL-8 receptor homolog. Science 1994, 265:682-684.
26. Gao JL, Wynn TA, Chang Y, Lee EJ, Broxmeyer HE, Cooper S, Tiffany HL, Westphal H, Kwon CJ, Murphy PM: Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med 1997, 185:1959-1968.
27. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897. This is a validation in an animal model of the long-held hypothesis that MCP-1 acts to recruit monocytes to atherosclerotic plaques and that the MCP-1 receptor (CCR2) is a target for therapy in atherosclerosis.
28. Zhou Y, Kurihara T, Ryseck RO, Yang Y, Ryan C, Loy J, Warr G, Bravo R: Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998, 160:4018-4025.
29. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S et al.: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393:591-599.
30. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382:635-638.
31. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ: Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998, 187:601-608.
32. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998, 2:275-281.
33. Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, Smithies O: Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995, 269:1 583-1585.
34. Rothenberg ME, MacLean JA, Pearlman E, Luster AD, Leder P: Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997, 185:785-790.
35. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapouméroulie C, Cognaux J, Forceille C et al.: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
36. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
37. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, GompErts E et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Science 1996, 273:1856-1862.
38. Folkesson HG, Matthay MA, Hebert CA, Broaddus VC: Acid-aspiration induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms. J Clin Invest 1995, 96:107-116.
39. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K: Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993, 365:654-657.
40. Matsumoto T, Yokoi K, Mukaida N, Harada A, Yamashita J, Watanabe Y, Matsushima K: Pivotal role of interleukin-8 in the acute respiratory distress syndrome and cerebral reperfusion injury. J Leukocyte Biol 1997, 62:581-587.
41. Gonzalo J-A, Lloyd CM, Wen D, Albar JP, Wells TNC, Proudfoot A, Martinez AC, Dorf M, Bjerke T, Coyle AJ, Gutierrez-Ramos J-C: The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998, 188:157-167. This is a comparison of the effects of blocking different chemokines and receptors in an in vivo model.
42. Karpus WJ, Kennedy KJ: MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as TH1/TH2 lymphocyte differentiation. J Leukocyte Biol 1997, 62:681-687.
43. Jones SA, Wolf M, Qin S, Mackay CR, Baggiolini M: Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2. Proc Natl Acad Sci USA 1996, 93:6682-6686.
44. Gong JH, Uguccioni M, Dewald B, Baggiolini M, Clark-Lewis I: RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem 1996, 271:10521-10527.
45. 2-terminal residues. J Exp Med 1995, 181:631-640.
46. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I: An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997, 186:131-137.
47. Proudfoot AEI, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells TNC: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996, 271:2599-2603.
48. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AEI, Power CA, Wells TNC: Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 1997, 57:57-60.
49. Lloyd CM, Minto AW, Dorf ME, Proudfoot AEI, Wells TNC, Salant DJ, Gutierrez-Ramos JC: RANTES and monocyte chemoattractant protein 1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997, 185:1371-1380.
50. Zagorski J, Wahl SM: Inhibition of acute peritoneal inflammation in rats by a cytokine induced neutrophil chemoattractant receptor antagonist. J Immunol 1997, 159:1059-1062.
51. McKinnon M, Proudfoot AEI, Wells TNC, Solari R: Strategies for the discovery of cytokine receptor antagonists. Drug News Perspect 1996, 9:389-398.
52. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, Sarau HM: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998, 273:10095-10098. This is the first publication of a small-molecule inhibitor of a chemokine receptor - confirming that chemokines may be the rare cytokine receptors for which small molecule antagonists with nanomolar potency can be found.
53. Schwarz MK, Wells TNC: Strategies for interfering with chemokine networks. Expert Opin Ther Pat 1999, 9:in press.
54. Hesselgesser J, Ng HP, Liang M, Zheng W, May K, Baumann JG, Monahan S, Islam I, Wei GP, Ghannam A et al: Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 1998, 273:15687-15692.
55. Bright C, Brown TJ, Cox P, Halley F, Lockey P, McLay IM, Moore U, Porter B, Williams RJ: Identification of a non peptidic RANTES antagonist. Bioorg Med Chem Lett 1998, 8:771-774.
56. Saunders J, Tarby CM: Opportunities for novel therapeutic agents acting at chemokine receptors. Drug Discov Today 1999, 4:80-92.
57. th National Medicinal Chemistry Symposium (Part I), Richmond, VA, USA, June 14-18 1998.
58. Horuk R: Chemokine receptors and HIV-1: The fusion of two major research fields. Immunol Today 1999, 20:89-94.
59. Schols D, Struyf S, Van Damme J, Esté JA, Henson G, De Clercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997, 186:1383-1388.
60. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De ClErcq E, Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998, 4:72-77.
61. B receptors. This opens up the intriguing possibility that chemokine receptors themselves heterodimerise, changing selectivity or signalling.
62. Rodriguez-Frade JM, Vila-Coro AJ, Martin de Ana A, Albar JP, Martinez AC, Mellado M: The chemokine monocyte chemoattractant protein-1 induces functional response through dimerization of its receptor CCR2. Proc Natl Acad Sci USA 1999, 96:3628-3633.
63. Rajarathnam K, Sykes BD, Kay CM, Dewald B, Geiser T, Baggiolini M, Clark-Lewis I: Neutrophil activation by monomeric interleukin-8. Science 1994, 264:90-92.
64. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y et al.: A small-molecule, nonpeptide CCR5 antagonists with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999, 96:5698-5703.
65. Luster AD: Chemokines - chemotactic cytokines that mediate inflammation. New Eng J Med 1998, 338:436-445.
66. Chung C, Cooke RM, Proudfoot AEI, Wells TNC: The three-dimensional solution structure of RANTES. Biochemistry 1995, 34:9307-9314.
67. Wells TNC, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM, Chung CW, Peitsch MC, Proudfoot AE: Selectivity and antagonism of chemokine receptors. J Leukocyte Biol 1996, 59:53-60.
68. Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, Van Riper G, Bondy S, Rosen H, Springer MS: Two-site binding of C5a by its receptoran alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 1994, 91:1214-1218.
69. Pakianathan DR, Kuta EG, Artis DR, Skelton NJ, Hebert CA: Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 1997, 36:9642-9648.